Table 1—

Selected characteristics of subjects included in the efficacy analysis

CharacteristicPlaceboFidarestatP
n10290
Age (years)56.7 ± 0.757.3 ± 0.90.60
Sex0.48
 Male55 (53.9)54 (60.0)
 Female47 (46.1)36 (40.0)
BMI (kg/m2)23.3 ± 0.422.9 ± 0.30.39
Duration of diabetes (months)180.4 ± 10.0169.7 ± 9.40.44
Type of diabetes1.00
 Type 15 (4.9)4 (4.4)
 Type 297 (95.1)86 (95.6)
HbA1c (%)8.0 ± 0.27.7 ± 0.10.23
Treatment for diabetes0.99
 No medication6 (5.9)6 (6.7)
 Oral hypoglycemic agent47 (46.1)40 (44.4)
 Insulin41 (40.2)37 (41.1)
 Oral hypoglycemic agent/Insulin8 (7.8)7 (7.8)
Diabetic retinopathy0.76
 No36 (35.3)37 (41.1)
 Simple31 (30.4)19 (21.1)
 Preproliferative15 (14.7)17 (18.9)
 Proliferative20 (19.6)17 (18.9)
Diabetic proteinuria0.68
 No62 (60.8)52 (57.8)
 Intermittent20 (19.6)19 (21.1)
 Persistent20 (19.6)19 (21.1)
  • Data are n, means ± SEM, or n (%).